* An article in the Sept. 19, 1996, BioWorld Today on an FDAadvisory committee meeting incorrectly stated that the drugcopolymer 1 slowed the progression of multiple sclerosis. The articlealso should have stated that the drug reduces the rate of relapses by22 percent.
* An article in the Sept. 24, 1996, BioWorld Today on AxiomBiotechnologies Inc., of San Diego, should have said the company'spartner, Zaiya Inc., of Kyoto, Japan, was founded one year ago andits president, Hiroki Yoshihara, also is president and CEO ofTranspect Inc., a biomedical consulting firm.
(c) 1997 American Health Consultants. All rights reserved.